This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on june 28, 2019.Upon further investigation of the reported event, the following information is new and/or changed: d4 additional device information - added exp date; e1 corrected last name; g4 date received by manufacturer; g7 indication that this is a follow-up report; h2 follow-up due to correction and additional information; h4 device manufacture date; h6 identification of evaluation codes (11, 3331, 4114, 213, 67.Method code #1: 11 - testing of device from same lot/batch retained by manufacturer.Method code #2: 3331- analysis of production records.Method code #3: 4114 - device not returned.Results code: 213 - no device problem found.Conclusions code: 67 - no problem detected.The sample was not returned for evaluation.A retention sample from the same product/lot number was tested and found to be functioning properly.An engineering investigation and capa have been initiated to determine a definitive root cause.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|